Roche's Long View: ASCO Marks Progress In Shifting To Lengthier Treatment Duration For Avastin, Rituxan

CHICAGO - Roche's current focus in oncology is on establishing longer treatment durations for its oncologics, including its mega-blockbuster Avastin (bevacizumab)